the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
Official Title A Phase Ib/II, Open-label, Multi-center Study of INC280 in Combination With PDR001 or PDR001 Single Agent in Advanced Hepatocellular Carcinoma.
Principal Investigator Sharma, Manish
Brief Summary The purpose of this study of INC280 and PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v. as a single agent or in combination with INC280 administered orally in adult patients with advanced hepatocellular carcinoma (HCC).
Gender All
Ages 18 Years
Enrollment 108
Accepts Healthy Volunteers No
Lead Sponsor Novartis PharmaceuticalsIndustry
Collaborator
Study Design
Study Phase Phase 1/Phase 2
Study Type Interventional
Contact Name Manish Sharma
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Advanced Hepatocellular Carcinoma
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI